Tumoral and Immune Heterogeneity in an Anti-Pd-1 Responsive Glioblastoma: A Case Study

Cold Spring Harbor molecular case studies - United States
doi 10.1101/mcs.a004762
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

Effect of Combined Anti-Pd-1 and Temozolomide Therapy in Glioblastoma

OncoImmunology
OncologyAllergyImmunology
2018English

P3.09-05 Significance of the Expression of PD-L1/PD-1 by Tumoral and Immune Cells in Non-Small Cell Lung Cancer.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2020English

Crosslink Between Temozolomide and PD-L1 Immune-Checkpoint Inhibition in Glioblastoma Multiforme

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Expression of LAG-3 and Efficacy of Combination Treatment With Anti-Lag-3 and Anti-Pd-1 Monoclonal Antibodies in Glioblastoma

International Journal of Cancer
Cancer ResearchOncology
2018English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-Pd-1 Therapy

Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy